Allogene Therapeutics Total Assets

Allogene Therapeutics posts a total assets of $400M as of March 2026. That compares with $510M in the prior-year period — down 22.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Allogene Therapeutics's total assets was $510M. The latest reading is $400M — a 22.1% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of Allogene Therapeutics's financial statement story. At $400M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ALLO's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Allogene Therapeutics's other metric pages and overview cover the third.

Judging Allogene Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $400M here, then scan peer and history charts to see if the gap is persistent.